PLoS ONE (Jan 2011)

Incidence, clinical features and impact on anti-tuberculosis treatment of anti-tuberculosis drug induced liver injury (ATLI) in China.

  • Penghui Shang,
  • Yinyin Xia,
  • Feiying Liu,
  • Xiaomeng Wang,
  • Yanli Yuan,
  • Daiyu Hu,
  • Dehua Tu,
  • Yixin Chen,
  • Peiyuan Deng,
  • Shiming Cheng,
  • Lin Zhou,
  • Yu Ma,
  • Lizhen Zhu,
  • Weiwei Gao,
  • Hongyuan Wang,
  • Dafang Chen,
  • Li Yang,
  • Pingping He,
  • Shanshan Wu,
  • Shaowen Tang,
  • Xiaozhen Lv,
  • Zheng Shu,
  • Yuan Zhang,
  • Zhirong Yang,
  • Yan Chen,
  • Na Li,
  • Feng Sun,
  • Feng Sun,
  • Xiaoting Li,
  • Yingjian He,
  • Paul Garner,
  • Siyan Zhan

DOI
https://doi.org/10.1371/journal.pone.0021836
Journal volume & issue
Vol. 6, no. 7
p. e21836

Abstract

Read online

BackgroundAnti-tuberculosis drug induced liver injury (ATLI) is emerging as a significant threat to tuberculosis control in China, though limited data is available about the burden of ATLI at population level. This study aimed to estimate the incidence of ATLI, to better understand its clinical features, and to evaluate its impact on anti-tuberculosis (TB) treatment in China.Methodology/principal findingsIn a population-based prospective study, we monitored 4,304 TB patients receiving directly observed treatment strategy (DOTS) treatment, and found that 106 patients developed ATLI with a cumulative incidence of 2.55% (95% Confidence Interval [CI], 2.04%-3.06%). Nausea, vomiting and anorexia were the top three most frequently observed symptoms. There were 35 (33.02%) ATLI patients with no symptoms, including 8 with severe hepatotoxicity. Regarding the prognosis of ATLI, 84 cases (79.25%) recovered, 18 (16.98%) improved, 2 (1.89%) failed to respond to the treatment with continued elevation of serum alanine aminotransferase, and 2 (1.89%) died as result of ATLI. Of all the ATLI cases, 74 (69.81%) cases changed their anti-TB treatment, including 4 (3.77%) cases with medication administration change, 21 (19.81%) cases with drugs replacement, 54 (50.94%) cases with therapy interruption, and 12 (11.32%) cases who discontinued therapy. In terms of treatment outcomes, 53 (51.46%) cases had TB cured in time, 48 (46.60%) cases had therapy prolonged, and 2 (1.94%) cases died. Compared with non-ATLI patients, ATLI patients had a 9.25-fold (95%CI, 5.69-15.05) risk of unsuccessful anti-TB treatment outcomes and a 2.11-fold (95%CI, 1.23-3.60) risk of prolonged intensive treatment phase.Conclusions/significanceATLI could considerably impact the outcomes of anti-TB treatment. Given the incidence of ATLI and the size of TB population in China, the negative impact is substantial. Therefore, more research and efforts are warranted in order to enhance the diagnosis and the prevention of ATLI.